{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Resectable+Lung+Non-Small+Cell+Carcinoma&page=2", "query": { "condition": "Resectable Lung Non-Small Cell Carcinoma", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Resectable+Lung+Non-Small+Cell+Carcinoma&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-11T03:33:58.829Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05742607", "title": "IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non Small Cell Lung Cancer" ], "interventions": [ { "name": "IPH5201 + durvalumab + standard chemotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Innate Pharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 70, "start_date": "2023-06-23", "completion_date": "2026-09", "has_results": false, "last_update_posted_date": "2025-05-16", "last_synced_at": "2026-06-11T03:33:58.829Z", "location_count": 6, "location_summary": "St. Petersburg, Florida • Tampa, Florida • Chicago, Illinois + 3 more", "locations": [ { "city": "St. Petersburg", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Lake Success", "state": "New York" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05742607" }, { "nct_id": "NCT01159964", "title": "Evaluation of a New Anti-cancer Vaccine for Patients With Non-small Cell Lung Cancer, After Tumor Removal by Surgery", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lung Cancer, Non-Small Cell" ], "interventions": [ { "name": "Immunotherapeutic GSK2302032A, different formulations", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2010-07-20", "completion_date": "2014-09-10", "has_results": false, "last_update_posted_date": "2018-06-18", "last_synced_at": "2026-06-11T03:33:58.829Z", "location_count": 7, "location_summary": "Newark, Delaware • Boston, Massachusetts • Rochester, Minnesota + 4 more", "locations": [ { "city": "Newark", "state": "Delaware" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "New York", "state": "New York" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01159964" }, { "nct_id": "NCT04351555", "title": "A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Osimertinib", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 358, "start_date": "2020-12-16", "completion_date": "2029-06-13", "has_results": true, "last_update_posted_date": "2026-06-05", "last_synced_at": "2026-06-11T03:33:58.829Z", "location_count": 12, "location_summary": "Duarte, California • Irvine, California • San Francisco, California + 9 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Santa Rosa", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04351555" }, { "nct_id": "NCT07630168", "title": "Effects of Infusion Timing on Treatment Response in Solid Tumors", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Cancer", "Non-small Cell Lung Cancer", "Metastatic Lung Cancer", "Head and Neck Cancer", "Metastatic Squamous Cell Carcinoma", "Metastatic Head and Neck Cancer", "Resectable Head and Neck Squamous-cell Carcinoma" ], "interventions": [ { "name": "PD-1/PD-L1 inhibitor monotherapy - 4 cycles before 12:00PM", "type": "DRUG" }, { "name": "PD-1/PD-L1 inhibitor monotherapy - 4 cycles after 3 PM", "type": "DRUG" }, { "name": "PD-1 inhibitor monotherapy - 2 cycles before 12:00PM", "type": "DRUG" }, { "name": "PD-1 inhibitor monotherapy - 2 cycles after 3 PM", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "UNC Lineberger Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 238, "start_date": "2026-06-01", "completion_date": "2033-01-01", "has_results": false, "last_update_posted_date": "2026-06-05", "last_synced_at": "2026-06-11T03:33:58.829Z", "location_count": 1, "location_summary": "Chapel Hill, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT07630168" }, { "nct_id": "NCT01443078", "title": "Neoadjuvant Platinum-based Chemotherapy for Patients With Resectable , Non-small Cell Lung Cancer With Switch to Chemotherapy Alternative in Nonresponders (NEOSCAN)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "pemetrexed", "type": "DRUG" }, { "name": "cisplatin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Gemcitabine Hydrochloride", "type": "DRUG" }, { "name": "Vinorelbine Tartrate", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 42, "start_date": "2011-10", "completion_date": "2015-04", "has_results": true, "last_update_posted_date": "2018-08-09", "last_synced_at": "2026-06-11T03:33:58.829Z", "location_count": 5, "location_summary": "Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Rockville Centre", "state": "New York" }, { "city": "Sleepy Hollow", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01443078" }, { "nct_id": "NCT00006212", "title": "Phosphorus-32 Plus Radiation Therapy and Chemotherapy in Treating Patients With Stage II or Stage III Non-small Cell Lung Cancer", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "cisplatin", "type": "DRUG" }, { "name": "vinblastine sulfate", "type": "DRUG" }, { "name": "phosphorus P32", "type": "RADIATION" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Center for Molecular Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "1999-11", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-09-17", "last_synced_at": "2026-06-11T03:33:58.829Z", "location_count": 1, "location_summary": "Garden City, New York", "locations": [ { "city": "Garden City", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00006212" }, { "nct_id": "NCT05925530", "title": "Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "Durvalumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 142, "start_date": "2024-02-22", "completion_date": "2027-08-27", "has_results": false, "last_update_posted_date": "2026-04-16", "last_synced_at": "2026-06-11T03:33:58.829Z", "location_count": 3, "location_summary": "The Bronx, New York • Houston, Texas • Charlottesville, Virginia", "locations": [ { "city": "The Bronx", "state": "New York" }, { "city": "Houston", "state": "Texas" }, { "city": "Charlottesville", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05925530" }, { "nct_id": "NCT04933903", "title": "BrUOG 397: NEO Rad (LOW): Neoadjuvant Low Dose Stereotactic Body Radiotherapy, Ipilimumab and Nivolumab", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non Small Cell Lung Cancer" ], "interventions": [ { "name": "Ipilimumab", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "SBRT", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Brown University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2021-10-05", "completion_date": "2026-09", "has_results": false, "last_update_posted_date": "2026-03-31", "last_synced_at": "2026-06-11T03:33:58.829Z", "location_count": 1, "location_summary": "Providence, Rhode Island", "locations": [ { "city": "Providence", "state": "Rhode Island" } ], "official_url": "https://clinicaltrials.gov/study/NCT04933903" }, { "nct_id": "NCT04025879", "title": "A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung" ], "interventions": [ { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 461, "start_date": "2019-11-05", "completion_date": "2027-07-30", "has_results": true, "last_update_posted_date": "2025-10-16", "last_synced_at": "2026-06-11T03:33:58.829Z", "location_count": 15, "location_summary": "Tampa, Florida • Atlanta, Georgia • Augusta, Georgia + 11 more", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT04025879" }, { "nct_id": "NCT02987998", "title": "Neoadjuvant Chemoradiation Plus Pembrolizumab Followed By Consolidation Pembrolizumab in NSCLC", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Stage IIIA Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Cisplatin", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Radiation", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nathan Pennell, MD, PhD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2017-05-19", "completion_date": "2022-11-28", "has_results": false, "last_update_posted_date": "2022-12-19", "last_synced_at": "2026-06-11T03:33:58.829Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02987998" } ] }